Gastrointestinal symptoms in COVID-19 patients

Marija Branković; Igor Jovanović; Tijana Radonjić; Igor Pančevski; Ilija Bukurecki; Marija Dukić; Višeslav Popadić; Slobodan Klašnja; Marija Zdravković

doi:10.2298/VSP210908014B

Marija Branković University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Igor Jovanović University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Tijana Radonjić University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Igor Pančevski Military Medical Academy, Clinic for Ophthalmology, Belgrade, Serbia
Ilija Bukurecki University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Marija Dukić University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Višeslav Popadić University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Slobodan Klašnja University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia
Marija Zdravković University Hospital Medical Center “Bežanijska Kosa”, Department of Internal Medicine, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP210908014B

Ključne reči: covid-19, dijagnoza, dijareja, ishrana, poremećaji, sars-cov-2, bolest, indeks težine, znaci i simptomi, digestivni, tomografija, kompjuterizovana, rendgenska

Sažetak

Uvod/Cilj. Teški akutni respiratorni sindrom korona virus 2 (SARS-CoV-2) je globalni problem i pretnja, i još uvek ima puno otvorenih pitanja. Cilj ispitivanja bio je da se utvrdi učestalost gastrointestinalnih (GI) simptoma kod hospitalizovanih bolesnika sa infekcijom prouzrokovanom SARS-CoV-2 (coronavirus disease-19 – COVID-19), kao i da se utvrdi da li ti bolesnici imaju viši skor intersticijalne pneumonije (IP) na pregledu pluća kompjuterizovanom tomografijom (KT) u odnosu na bolesnike sa COVID-19 bez GI tegoba. Metode. Ispitivanje je obuhvatilo 322 hospitalizovana bolesnika sa COVID-19 koji su bili podeljeni u dve grupe: grupu sa GI simptomima i grupu bez GI simptoma. Svi podaci su dobijeni anamnestički i iz istorije bolesti bolesnika, a nakon toga su statistički obrađeni. Rezultati. Od 322 bolesnika, 206 (63.9%) je imalo opisanu obostranu IP na KT pregledu grudnog koša, a 76 bolesnika (36.9%) imalo je opisanu IP u vrhuncu bolesti. Takođe, 130 bolesnika (40.4%) prijavilo je GI simptome, čak 58 od 130 bolesnika (44.6%) je anamnestički navelo da su GI simptomi bili prva manifestacija COVID-19 infekcije. Najčešći simptom bio je gubitak apetita [kod 73 bolesnika (56.15%)]. Od 130 bolesnika sa GI simptomima, 65 (50%) je prijavilo dijareju, 25 (19.23%) mučninu i povraćanje, a 9 (6.9%) bolesnika prijavilo je bol u trbuhu. Bolesnici sa obostranom IP i GI simptomima [31 (40.8%)] na vrhuncu bolesti nisu imali veću zahvaćenost plućnog parenhima IP na pregledu grudnog koša KT, u poređenju sa bolesnicima bez GI simptoma [45 (59.21%)], (p = 0.704). Zaključak. GI simptomi su često prva manifestacija COVID-19. Stoga, kod svih bolesnika sa novonastalim digestivnim simptomima treba proveriti postojanje COVID-19. S druge strane, prisustvo GI simptoma ne ukazuje na to da će bolesnici sa COVID-19 imati teži oblik IP.

Reference

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470–3.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565–74.

Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and Older Adults: What We Know. J Am Geriatr Soc 2020; 68(5): 926–9.

Burki TK. Coronavirus in China. Lancet Respir 2020; 8(3): 238.

Hajifathalian K, Mahadev S, Schwartz RE, Shah S, Sampath K, Schnoll-Sussman F, et al. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. World J Gas-troenterol 2020; 26(14): 1546–53.

Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesiel-ka M, Sitarz E, et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J Clin Med 2020; 9(6): 1753.

Lee KS, Han J, Chung MP, Jeong YJ. Consolidation. Radiol Il-lust Chest Radiol 2013; 221–33.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506.

Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA 2020; 323(14): 1406–7.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–62.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemi-ological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–13.

Ellulu MS, Patimah I, Khaza H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017; 13(4): 851–63.

Albini A, Di Guardo G, Noonan DMC, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many differ-ent cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg Med 2020; 15(5): 759–66.

Schmulson M, Dávalos MF, Berumen J. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19 (Spanish). Rev Gastroenterol Mex 2020; 85(3): 282–7.

Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Me-tabolism 2019; 92: 6–10.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, Mcginn T, Davidson KW. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA 2020; 323(20): 2052–9.

Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (stand-ard version). Mil Med Res 2020; 7(1): 4.

Chan JF, Yuan S, Kok K, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel corona-virus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223): 514–23.

Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coro-navirus (2019-nCoV) Pneumonia. Radiology 2020; 295(1): 18.

Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology 2020; 295(3): 200463.

Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology 2020; 295(1): 202–7.

Neurath MF. Covid-19 and immunomodulation in IBD. Gut 2020; 69(7): 1335–42.

Yang L, Tu L. Implications of gastrointestinal manifestations of COVID-19. Lancet Gastroenterol Hepatol 2020; 5(7): 629–30.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–9.

Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut 2020; 69: 1010–8.

Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020; 158(6): 1831–1833.e3.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recogni-tion by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Corona-virus. J Virol 2020; 94(7): e00127‒20.

Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epi-demiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gas-trointestinal symptoms. Gut 2020; 69(6): 1002–9.

Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, et al. Diarrhea is associated with prolonged symptoms and viral car-riage in COVID-19. Clin Gastroenterol Hepatol. (2020) 18:1753–9.e2.

Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, et al. Clinical Characteristics of SARS-CoV-2 Infected Pneumonia with Diarrhea. 2020. Available from: https://papers.ssrn.com › papers

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708–20.

Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symp-toms in Hubei, China: A descriptive, cross-sectional, multi-center study. Am J Gastroenterol 2020; 115(5): 766–73.

Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020; 5(5): 434–5.

Chen L, Lou J, Bai Y, Wang M. COVID-19 Disease with Posi-tive Fecal and Negative Pharyngeal and Sputum Viral Tests. Am J Gastroenterol 2020; 115(5): 790.

WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec 2003; 78(43): 373‒5. (English, French)

Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol 2020; 35(5): 744–8.

Yeo C, Kaushal S, Yeo D. Enteric involvement of coronavirus-es: is faecal-oral transmission of SARS-CoV-2 possible? Lan-cet Gastroenterol Hepatol 2020; 5(4): 335–7.

Gastrointestinalni simptomi bolesnika sa COVID-19

Sažetak

Reference